Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.51 |
| ▸ | ATP4A | P20648 | 2/20 | 0.41 |
| ▸ | ATP4B | P51164 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.40 |
| ▸ | GLA | P06280 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5047315 | 0.81 | PTPN1 (0.46) | PTPN1ATP4AATP4BPTGDR2GLA | |
| SCHEMBL4260587 | 0.79 | PTPN1 (0.53) | PTPN1CYP1A2 | |
| SCHEMBL7501649 | 0.67 | PTPN1 (1.00) | PTPN1 | |
| SCHEMBL4266628 | 0.66 | PTPN1 (0.56) | PTPN1 | |
| SCHEMBL10662986 | 0.65 | ATP4A (0.56) | ATP4AATP4BPTGDR2MAPTCYP1A2 | |
| SCHEMBL975594 | 0.65 | CDC7 (0.62) | — | |
| SCHEMBL4260600 | 0.64 | PTPN1 (0.51) | PTPN1MAPTCYP1A2 | |
| SCHEMBL1435329 | 0.63 | PPARG (0.57) | PTPN1 | |
| SCHEMBL21881586 | 0.62 | KDM4E (0.55) | PTPN1 | |
| SCHEMBL13324879 | 0.62 | KDM4E (0.55) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633354-B1 | N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES | INST FOR PHARM DISCOVERY INC (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1633354-A2 | N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES | The Institutes for Pharmaceutical Discovery, LLC (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20040248937-A1 | Substituted phenylalkanoic acids for the treatment of diabetes | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2004-12-09 | — | — | US | disclosed |
| WO-2004092146-A2 | N- (((((1,3-THIAZOL-2-YL) AMINO) CARBONYL) PHENYL) SULFONYL) PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248937-A1 | Substituted phenylalkanoic acids for the treatment of diabetes | PTP4A1, PTPRJ, PPM1B | PTPN1 4/4885ATP4A 546/4885ATP4B 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.